公司活动安排 - 公司将于2025年9月3日美东时间上午9:45参加Cantor全球医疗保健会议 [1] - 公司将于2025年9月8日美东时间下午2:00参加H C Wainwright第27届全球投资会议 [1] - 活动网络直播可在投资者关系网站获取 录播将在活动结束后约2小时上线并存档90天 [2] 公司业务定位 - 公司处于商业化阶段的生物制药企业 专注于满足患者和医疗专业人员未满足需求的创新药物 [3] - 公司开发并商业化美国FDA批准的唯一口服、每日一次、非他汀类降胆固醇药物 针对心血管疾病风险且低密度脂蛋白胆固醇升高的患者 [3] - 药物疗效得到近14,000名患者参与的CLEAR心血管结局试验支持 [3] 研发管线进展 - 下一代研发项目聚焦于ATP柠檬酸裂解酶抑制剂(ACLYi)开发 [3] - 对ACLYi结构和功能的新见解支持理性药物设计 有望开发具有变构机制的高效特异性抑制剂 [3] 战略发展方向 - 公司通过商业化执行、国际合作伙伴关系及临床前管线推进 持续发展为全球领先的生物制药企业 [4]

Wall Street analysts forecast that Colgate-Palmolive (CL) will report quarterly earnings of $0.89 per share in its upcoming release, pointing to a year-over-year decline of 2.2%. It is anticipated that revenues will amount to $5.06 billion, exhibiting no change compared to compared to the year-ago quarter. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reass ...

Colgate-Palmolive (NYSE: CL ) introduces itself in its annual report as a "caring, innovative growth company reimagining a healthier future for all people, their pets, and our planet." The company is operating in two segments: oral, personal, and home Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seekin ...

ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Esperion Contact Information: Investors: Alina Venezia investorrelations@esperion.com (734) 887-3903 Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438 Esperion Therapeu ...